There has been increasing concern over recent years regarding the potential link between glyphosate (the active ingredient in many weed killers, including RoundUp) and developing Non-Hodgkin’s Lymphoma, a type of cancer. This concern largely stems from the IARC’s classification of glyphosate as a “probable human carcinogen” and has resulted in a number of successful multiple pursuer court cases overseas against Bayer, the producers of the product.
These cases have led to large sums of compensation being agreed. Although to date, these actions have been brought in countries such as the United States and Canada where group (multiple pursuer) proceedings are more common, it is reasonable to assume that there is scope for similar cases to be successful in the UK, where the chemical constitution of the product is the same.
Interestingly, Bayer has announced that it will stop selling glyphosate-based herbicides for residential use in the US beginning in 2023 with a view to managing the risk of future litigation however it is unknown whether it intends to do the same in the UK.
If you or a family member has been diagnosed with Non-Hogkin’s Lymphoma following significant use of RoundUp either at work or at home (i.e. twice within a 12 month period and at least 10 applications within a lifetime) then please contact MedNegDM@drummondmiller.co.uk or call 0131 221 2538 to discuss whether you may have a claim for compensation.
Take the next step
- Call us on 0131 226 5151